Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash & Equivalents (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Cash & Equivalents data on record, last reported at $301.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 16.23% year-over-year to $301.6 million; the TTM value through Sep 2025 reached $301.6 million, down 16.23%, while the annual FY2024 figure was $319.7 million, 462.36% up from the prior year.
  • Cash & Equivalents reached $301.6 million in Q3 2025 per ZBIO's latest filing, up from $44.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $360.0 million in Q3 2024 and bottomed at $37.2 million in Q1 2024.
  • Average Cash & Equivalents over 3 years is $174.7 million, with a median of $183.9 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 462.36% in 2024, then crashed 76.07% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $56.9 million in 2023, then skyrocketed by 462.36% to $319.7 million in 2024, then decreased by 5.67% to $301.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $301.6 million in Q3 2025, $44.0 million in Q2 2025, and $196.6 million in Q1 2025.